HDAC2 as a target for developing anti-cancer drugs

Hyein Jo; Kyeonghee Shim; Han-Ul Kim; Hyun Suk Jung; Dooil Jeoung

doi:10.1016/j.csbj.2023.03.016

HDAC2 as a target for developing anti-cancer drugs

Comput Struct Biotechnol J. 2023 Mar 13:21:2048-2057. doi: 10.1016/j.csbj.2023.03.016. eCollection 2023.

Authors

Hyein Jo¹, Kyeonghee Shim¹, Han-Ul Kim¹, Hyun Suk Jung¹, Dooil Jeoung¹

Affiliation

¹ Department of Biochemistry, College of Natural Sciences, Kangwon National University, Chuncheon 24341, Republic of Korea.

Abstract

Histone deacetylases (HDACs) deacetylate histones H3 and H4. An imbalance between histone acetylation and deacetylation can lead to various diseases. HDAC2 is present in the nucleus. It plays a critical role in modifying chromatin structures and regulates the expression of various genes by functioning as a transcriptional regulator. The roles of HDAC2 in tumorigenesis and anti-cancer drug resistance are discussed in this review. Several reports suggested that HDAC2 is a prognostic marker of various cancers. The roles of microRNAs (miRNAs) that directly regulate the expression of HDAC2 in tumorigenesis are also discussed in this review. This review also presents HDAC2 as a valuable target for developing anti-cancer drugs.

Keywords: Anti-cancer drug resistance; Anti-cancer drugs; CAGE, cancer associated gene; DNMT1, DNA methyl transferase 1; EMT, epithelial to mesenchymal transition; GC, gastric cancer; HCC, hepatic cell carcinoma; HDAC2, histone deacetylase 2; Histone deacetylase 2; NSCLC, non-small cell lung cancers; PTEN, phosphatase and tensin homolog deleted on chromosome 10; Prognostic marker; Tumorigenesis; miRNAs, micro RNAs.

Publication types

Review